Powered by
MILAN, Italy—Dipharma Francis S.r.l., a contract development and manufacturing organization for the pharmaceutical industry, announced the completion of the new cGMP Quality Control laboratory and c-GMP kilolab at its Kalamazoo …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) announced that the U.S. Food and Drug Administration (FDA) approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin cholesterol-lowering medicine. Nexletol is indicated as an …
ALLENDALE—QST Consultations Ltd. has announced that it has changed its name to Abond CRO Inc., launching the new brand through a new website and participation at participation at the Summit …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced that Christophe Arbet-Engels has joined the company as Chief Medical …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a “positive opinion” for both its bempedoic …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), the developer of new endocrine drugs, announced the promotion of Thomas Hoover to the newly created position of chief commercial officer. Hoover joined Millendo …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, announced that Geoff Nichol has been appointed …
ANN ARBOR—Phenomics Health Inc., a University of Michigan research spinout that aims to increase the precision of pharmaceuticals by using individual people’s genetic information, announced it acquired patented pharmacometabolomic technology …
CANTON TWP.–MMS Holdings Inc., the contract research organization for the pharmaceutical industry based in Canton Township, announced that its regional operations in South Africa more than doubled in the past …
ANN ARBOR—Millendo Therapeutics Inc., (Nasdaq: MLND), a clinical-stage pharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, provided a corporate update and reported …